Mayroong isang malaking tagumpay sa pag-unlad ng gamot sa tumor sa utak ng bata. Ang mga bukol sa utak ng mga bata ay isang pangkaraniwang malignant na sakit sa mga bata. Kamakailang pananaliksik ay natagpuan na ang isang bagong gamot na cocktail ay maaaring magamot ang karaniwang mga bukol sa utak ng pagkabata.
Cancer Cell” magazine recently announced that in the UK, about 400 children develop brain mga bukol each year, of which the prevalence of boys is slightly higher than that of girls.
Are we able to take advantage of the results of tumor gene testing and tailor-made treatments, a strategy often referred to as personalized medicine? This treatment strategy can produce very good results for patients with brain tumors.
Neural myeloblastoma (medulloblastoma) is one of the most common mga malignant na bukol of the cerebellum. This utak ng utak grows rapidly and most often occurs in children around the age of 5. mga pagpipilian sa paggamot include surgery, radiation, and chemotherapy. Although great progress has been made in treatment methods and techniques, the success rate of treating myeloblastoma still lags far behind other children’s malignancies. In particular, myeloblastoma is a highly aggressive malignancy. Only 40% of patients with medulloblastoma survive, compared with other tumors of a less severe type-with a survival rate of more than 80%.
Researchers in the United States have discovered a new combination therapy for the treatment of highly aggressive neuroblastoma. In laboratory tests, the drug killed kanser cells without any toxicity to normal cells, and researchers hope to conduct clinical trials of the drug. Robert Wechsler-Reya, an adjunct professor at the Sanford Burnham Prebys Medical Institute, said: “Our goal is to confirm that the drug has low toxicity properties. Because doctors and patients in this case urgently require new clinical treatment options, we will soon apply the drug from the laboratory to clinical treatment.
Sa pamamagitan ng pagsasama sa iba pang mga gamot, ang mga bagong compound na pumipigil sa mga bukol ay na-screen in vitro at in vivo.
Klinikal na pagsubok for neuroblastoma are often very challenging because of the limited number of patients. In addition, coupled with the variability of the disease, most treatments are only effective for one subtype of patient. Understanding which patients will respond to this treatment is one of the main goals of the trial.
"Kung makakagawa tayo ng mga pagpapasadya na ginawa batay sa mga tumor genes-isang diskarte na karaniwang tinutukoy bilang indibidwal na paggamot-maaari itong magdala ng isang malaking ebanghelyo sa mga pasyente na may ilang mga bukol."
Mayroong apat na magkakaibang uri ng neuroblastoma, at ang mga pasyente na may pangatlong pangkat ng mga bukol ay mayroong pinakapangit na pagbabala — 40% lamang ng mga pasyente ang makakaligtas sa pangmatagalang. Sa kaibahan, ang pangmatagalang kaligtasan ng buhay ng iba pang mga neuroblastomas ay medyo maasahin sa mabuti, at halos 80% ng mga pasyente ang maaaring makaligtas sa pangmatagalang.
Karamihan sa pangatlong pangkat ng mga pasyente na may neuroblastoma ay may mataas na pagpapahayag ng MYC oncogene, na siyang sanhi ng hindi mapigil na dibisyon ng cell at pagbuo ng mga bukol.
There was a study on mice with a third type of neural tube cell tumors that showed histone deacetylase inhibitors (HDACIs) and phosphatidylinositol 3-kinase inhibitors (PI3KIs) might stop mice and people from making neurotubular glioblastomas without doing too much damage to normal cells.
We found several histone deacetylase inhibitors that can kill MYC oncogene-activated neural tube cell tumors without harming normal cell agents (HDACIs),” said Pei Yanxin, an assistant professor at the National Children’s Medical Center sa Washington, DC
The most effective of these compounds is panobinostat, which has entered clinical trials in other mga uri ng cancer, but has not yet been tested on neuroblastoma.” Dr. Kun-Wei, a postdoctoral researcher at Stanford University, added: “Several other studies have revealed that the mechanism of action of panobinostat is to promote the activation of the FOXO1 gene that can interfere with the oncogenes of MYC.
Phosphatidylinositol 3-kinase inhibitors (PI3KIs) are also thought to have the effect of activating the FOXO1 gene. We hypothesized that panobinostat and phosphatidylinositol 3-kinase inhibitors (PI3KIs) could work together to block Cell Cancer kaligtasan ng buhay.
“It is true that the combined treatment of these two drugs can significantly increase the survival of patients with tumors carrying the MYC gene compared to using a single drug alone.”
